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INTRODUCTION
Autoimmune diseases include more than 80 chronic 
disorders that affect nearly 5% of the population in 
Western countries. They are characterized by an exag-
gerated immune response leading to damage and dys-
function of specific or multiple organs and tissues. The 
aetiology of autoimmune diseases is still unknown, but 
the available evidence points to an interaction between 
genetic, environmental and life style factors in disease 
development. Autoimmune diseases are typically more 
prevalent in women than in men and are considered 
the fourth leading cause of disability for women [1]. 
The strongest sex bias is observed in Sjogren’s syn-
drome, systemic lupus erythematosus (SLE), autoim-
mune thyroid disease and scleroderma where the ratio 
of women to men is 7:1-10:1. In rheumatoid arthritis 
(RA), multiple sclerosis (MS) and myasthenia gravis, 
the female to male ratio is 2:1-3:1, while there is little 
or no sex bias in inflammatory bowel diseases and type 
1 diabetes [2-4]. Symptom severity, disease course, re-
sponse to therapy and overall survival may also differ 
between males and females with autoimmune diseases. 
In general, women mount stronger humoral and cellu-
lar immune responses than men and this is believed to 
have an effect on the different susceptibility to develop 
autoimmune diseases. The main factors affecting the 
differences between female and male immune systems 
are the sex hormones, the presence of two X chromo-
somes versus one X and one Y chromosome, and the 
different response to environmental factors, such as 
microbial exposure and diet [5]. Sociological differenc-
es between genders may also affect the development of 
autoimmunity. However, the discussion of this topic is 
beyond the scope of this article and readers can refer 
to recent reviews [6]. Here, we briefly review the role 
of sex-related factors in autoimmunity and then high-
light key discoveries and controversies on the role of 
sexual dimorphism in three paradigmatic autoimmune 
diseases: SLE, RA and MS.
SEX HORMONES IN AUTOIMMUNITY
Due to the presence of hormone receptors on im-
mune cells [7], sex hormones, such as estrogens, pro-
gesterone, androgens and prolactin, can influence 
different aspects of immune system function and po-
tentially affect the risk, activity and progression of au-
toimmune diseases. Generally, estrogens, in particular 
17-β estradiol (E2) and prolactin, act as enhancers at 
least of humoral immunity, and testosterone and pro-
gesterone as natural immunosuppressants [3]. Sex hor-
mones have different effects depending not only on the 
concentration but also on the type of target cell and 
the receptor subtype expressed on a given cell type. At 
periovulatory to pregnancy levels [8], E2 has mainly 
anti-inflammatory effects, by inhibiting production and 
signaling of pro-inflammatory cytokines, such as tumor 
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necrosis factor (TNF), interleukin (IL)-1β and IL-6, 
and natural killer (NK) cell activation, and by inducing 
expression of anti-inflammatory cytokines favoring a T 
helper 2 (Th2) phenotype [9], such as IL-4, IL-10 and 
transforming growth factor (TGF)-β, and by activating 
regulatory T cells (Treg) [10]. At lower concentrations, 
E2 stimulates TNF, interferon (IFN)-γ, IL-1β and NK 
cells, while it enhances antibody production by B cells 
both at high and low concentrations [9]. Prolactin in-
creases antibody production, regulates the develop-
ment of CD4+ T cells and triggers pro-inflammatory 
cytokine production [11]. Progesterone stimulates a 
switch from a predominantly pro-inflammatory to an 
anti-inflammatory immune response, favors Treg dif-
ferentiation [12], and exerts an inhibitory effect on 
NK cells. Several studies indicate that testosterone has 
suppressive effects on the immune system by inhibiting 
pro-inflammatory cytokine production, Th1 differentia-
tion, immunoglobulin production and NK cell cytotoxic 
activity, and by potentiating the expression of anti-in-
flammatory cytokines [13].
Consistent with the effects of sex hormones on im-
munity, changes in the severity of autoimmune diseases 
are observed during pregnancy, when estrogens and 
progesterone reach the highest levels [14]. Maternofe-
tal immune tolerance is essential to maintain pregnancy 
and one of the important adaptations leading to this 
immune tolerance is the shift, at implantation, from a 
pro-inflammatory Th1/Th17 response, which promotes 
rejection, toward a Th2/Treg cell response that pro-
motes tolerance and inhibits NK cell cytotoxicity. Due 
to these adaptive changes in immune system function, 
pregnancy has opposite effects on some autoimmune 
diseases. For instance, pregnancy is associated with an 
increase in disease flares in SLE, this effect being re-
lated to the increased Th2 response and enhanced pro-
duction of pathogenic autoantibodies [15]. Conversely, 
pregnancy has a protective effect in Th1-dominant im-
mune diseases, like RA and MS. 
SEX CHROMOSOMES IN AUTOIMMUNITY
The female karyotype includes two X chromosomes, 
one derived from each parent, while men carry one 
maternal X and one paternal Y chromosome. To avoid 
double dosage of X chromosome-derived proteins, one 
of the X chromosomes is randomly silenced in females 
in the early stages of embryogenesis. However, X chro-
mosome inactivation is not complete and about 15% 
of the genes escape inactivation, leading to overexpres-
sion of some X-linked genes in females [16]. The X 
chromosome encodes several immune-related genes, 
such as CD40 ligand, chemokine receptor CXCR3, O-
linked N-acetylglucosamine transferase, forkhead box 
P3(FOXP3), toll-like receptor (TLR)7, TLR8, IL-2 re-
ceptor gamma, tyrosine-protein kinase BTK, and IL-9 
receptor, whose overexpression may influence the im-
mune response in a sex-dependent manner [5]. An 
important role for genes on the partially inactivated X 
chromosome in immune system function is highlighted 
by the finding that both the absence of a normal sec-
ond X-chromosome in females (Turner syndrome) and 
the presence of two or more X chromosomes in males 
(Klinefelter syndrome) are associated with an altered 
susceptibility for some autoimmune diseases as com-
pared with sex-matched general population (e.g., SLE 
prevalence is decreased in Turner syndrome and in-
creased in Klinefelter syndrome) [17, 18]. Experimen-
tal studies suggest that the Y chromosome may play a 
protective role in the development of autoimmunity 
[19]. 
SEX DIFFERENCES IN microRNA 
EXPRESSION IN AUTOIMMUNITY
MicroRNAs (miRNAs) are short non-coding RNAs 
(19-24 nucleotides in length) that regulate gene expres-
sion mainly at the post-transcriptional level by binding 
to the 3’ UTR of target genes and inducing translational 
inhibition or degradation of the target mRNA. Their 
expression and function are essential for the develop-
ment of different physiological systems and the main-
tenance of cell homeostasis. Because miRNAs are criti-
cal for the development, differentiation and function of 
both innate and adaptive immune cells, dysregulation 
of their expression may contribute to the development 
of autoimmune diseases [20]. It has been reported that 
miRNAs are differentially expressed in males and fe-
males in both gonadal and non-gonadal tissues, but it 
is not clear yet what drives this sex-related differential 
expression. The X chromosome is highly enriched in 
miRNAs whereas only two miRNAs, at least in humans, 
have been assigned to the Y chromosome thus far [21]. 
Although most of the X-linked miRNAs have no known 
function, some of them are reported to play a role in 
immunity or autoimmunity [22, 23]. The presence of 
a second X chromosome in females can affect miRNA 
expression levels and this may be crucial for the devel-
opment of female biased-autoimmunity. Interestingly, 
E2 can regulate miRNA expression in different cell 
types and tissues, by both genomic and non-genomic 
mechanisms of action [24], while miRNAs regulate E2-
dependent signaling by targeting proteins and signaling 
molecules that are involved in estrogen signaling [22]. 
Exploring miRNAs in the context of sex-biased auto-
immune disorders may provide novel insights into dis-
ease pathogenesis and lead to the identification of new 
therapeutic targets.
SEX DIFFERENCES IN THE GUT 
MICROBIOTA
It is well established that gut microbiota (i.e., the col-
lection of bacteria, viruses, fungi and protozoa lining 
the gastrointestinal mucosa) affects innate and adaptive 
immune responses. On the other hand, the immune sys-
tem influences the composition of the gut microbiota 
and this interaction can have important consequences 
for the development of inflammatory diseases [25]. A 
role for gut microbiota in the sex bias in autoimmunity 
has been revealed by different studies in animal models. 
For instance, in the spontaneous NOD model of type 1 
diabetes characterized by a strong female bias, disease 
rate was similar in germ-free (GF) female and male 
NOD mice, suggesting that male-specific microbiota 
play a protective role [26]. This effect could be medi-
ated, at least partially, via microbiota metabolism of sex 
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hormones. In fact, gavage of female NOD weanlings 
with male NOD-derived intestinal microbiota resulted 
in elevated testosterone levels and type 1 diabetes pro-
tection as compared with unmanipulated females [26]. 
Conversely, sex hormones may affect gut microbiota 
because sex-specific differences in the composition of 
the microbiota are found only after puberty [26, 27]. 
Similarly to what observed in NOD mice, the composi-
tion of gut microbiota in mouse models of lupus and 
RA has been found to be significantly different in male 
and female adult mice [28, 29]. Summarizing, specific 
gut microbiota patterns appear to be associated with 
autoimmunity. However, the role of gut microbes and 
their interactions with hormones in the sex bias in au-
toimmunity is still poorly characterized and no data 
are available in humans. Further studies are needed 
to elucidate the specific mechanisms and/or molecules 
produced by gut commensals that are affected by and 
affect sex hormones, and may be involved in the protec-
tion from autoimmune diseases.
OTHER FACTORS POTENTIALLY INVOLVED 
IN THE SEX BIAS IN AUTOIMMUNITY
Microchimerism. Maternal and fetal cells are ex-
changed during pregnancy, leading to fetal cell persis-
tence in the mother (microchimerism). Chimeric fetal 
cells are often hematopoietic and can differentiate into 
somatic cells in different organs, becoming a potential 
target for autoimmunity [30]. The available data on the 
role of fetal microchimerism in autoimmunity are weak 
or inconclusive.
Environmental estrogens. In addition to endogenous es-
trogens, the immune system can be targeted by natural 
(phytoestrogens and mycoestrogens) or synthetic (xe-
noestrogens) compounds with estrogenic activity, i.e., 
estrogenic endocrine disruptors [31]. Xenoestrogens 
can be present in cosmetics and personal care products 
(makeup, hair dyes, soaps, perfumes) more commonly 
used by women. The actual impact of both endogenous 
and environmental estrogens on the immune system is 
still under investigation. Environmental estrogens may 
display a synergic/additive effect with endogenous es-
trogens potentially affecting the immune response. The 
influence of oral contraceptives and hormone replace-
ment therapy on the risk and progression of autoim-
mune disease in women also deserves consideration.
SYSTEMIC LUPUS ERYTHEMATOSUS
SLE is a multifactorial and highly polymorphic sys-
temic autoimmune disease that affects multiple organs 
including kidneys and heart [32]. The incidence of the 
disease is estimated at 20–50 cases/100 000 individu-
als. To date, the etiology of SLE remains unknown; 
however, it is likely that a complex interaction between 
genetic, environmental (e.g., infectious agents, includ-
ing Epstein-Barr virus and parvovirus, UV light, drugs, 
cigarette smoking and silica dust), and hormonal fac-
tors promotes the immune dysfunction leading to the 
disease. SLE is characterized by autoantibody produc-
tion by dysregulated B cells, target organ infiltration by 
inflammatory T cells and aberrant immune cell activa-
tion. The autoantigen-autoantibody interaction triggers 
the formation of immune complexes that, once depos-
ited, cause tissue injury [33].
SLE is often called a “woman’s disease” because of 
the striking differences in prevalence related to sex. 
Pre-menopausal women have SLE incidence rates of 
8:1-15:1 when compared to age-matched males; these 
rates decline to 3:1 in the pre-adolescent population 
and to 5:1 after menopause, when estrogen levels are 
more similar between genders. Clinical observations 
and experimental data clearly indicate that E2 influ-
ences the development of SLE [3, 34]. Studies in lupus 
experimental models have demonstrated that E2 pro-
motes disease via estrogen receptor (ER) α activation 
[35] whereas ERβ activation has mild immunosuppres-
sive effects [36]. ERα-deficient mice show significantly 
less aggressive renal disease and proteinuria and survive 
better than wild-type mice [37]. Importantly, an accel-
erated metabolic conversion of androgen precursors to 
E2, due to aromatase activation, has been observed in 
SLE, partially explaining the increased availability of 
E2 in this disease [38]. Moreover, the identification 
of autoantibodies reacting with ERα in SLE patients 
and their correlation with disease activity [39] have dis-
closed a new research area in estrogen-related effects 
in autoimmunity. Results from different studies indi-
cate that the use of oral contraceptives and hormone 
replacement therapy increases the risk of developing 
SLE; however, some retrospective studies suggest no 
increase in clinical flares with hormonal therapy [40]. 
Importantly, a reduction in disease activity has been 
observed in SLE patients treated with the pure ER an-
tagonist Fulvestrant (Faslodex) [41].
X-linked genes, such as FOXP3, TNF and TLR7, have 
been associated with gender bias in SLE [5]. Addition-
ally, several X-linked miRNAs have been found to be 
upregulated in CD4+ T cells from female SLE patients 
compared to male patients [22], potentially contribut-
ing to the sex bias in SLE. E2 may contribute to the 
gender bias in SLE by modulating expression of selected 
miRNAs [42]. miR146a, which is a negative regulator 
of the IFN-α pathway, and miR125a, which negatively 
regulates the inflammatory chemokine RANTES, are 
profoundly decreased in peripheral blood mononuclear 
cells from patients with SLE as compared to healthy do-
nors [43, 44]. Conversely, miR148a, which contributes 
to DNA hypomethylation in lupus CD4+ T cells, has 
been found up-regulated [45]. In splenocytes from es-
trogen-treated mice, miR148a was up-regulated where-
as miR146a and miR125a were down-regulated [46].
In males, SLE has a late onset and different clinical 
features and outcomes, suggesting that male-specific 
predisposing and/or pathogenetic factors exist. To date, 
there is limited evidence to suggest an altered hormonal 
milieu in men with lupus [47, 48]. Potential risk factors 
include X-chromosome abnormalities (as supported by 
the increased incidence of SLE in patients with Kline-
felter syndrome) and various somatic genetic polymor-
phisms. Further studies are required to understand the 
sex-related aspects of SLE disease susceptibility, clinical 
features and outcome, potentially providing new tools 
for clinical intervention. Sex-specific factors affecting 
SLE are summarized in Table 1.
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RHEUMATOID ARTHRITIS
RA affects approximately 1% of the general popula-
tion and is characterized by chronic joint inflamma-
tion, functional impairment, disability, and premature 
mortality. It is widely accepted that RA is caused by 
various environmental factors in genetically predisposed 
individuals. RA is about three times more common in 
women than in men, with a peak age of onset in the 
fifth decade of life. The female to male prevalence ratio 
is around 2:1 in 55 to 64-year-olds, shifting to a male 
excess in people over 75-years old. Data concerning fe-
male sex hormone exposure and RA risk are conflict-
ing [49]. The higher prevalence of RA in females than 
males, at least before 75 years of age, could suggest 
that E2 and progesterone increase the risk of disease. 
However, as stated above, RA presents more often after 
menopause, and past large cohort studies did not estab-
lish any relationship between oral contraceptives or hor-
mone replacement therapy and the risk of developing 
RA [40]. Nulliparity is associated with an increased risk 
of disease development whereas pregnancy seems to de-
crease it [50]. These data show, pregnancy effects apart, 
that the female to male ratio observed in RA probably 
involves factors other than E2 and progesterone. Re-
garding disease activity, whereas in animal models of RA 
female sex hormones have beneficial effects, their role in 
humans is less clear as both pro- and anti-inflammatory 
effects have been described. On the one hand, higher 
disease activity scores have been reported in women as 
compared to men [51]. Additionally, estrogens are sig-
nificantly elevated, relatively to androgens, in synovial 
fluid from both male and female RA patients; this is 
due to high aromatase activity that is induced by locally 
produced inflammatory cytokines, favoring macrophage 
and fibroblast proliferation and therefore the inflamma-
tory process [52]. On the other hand, the clinical fea-
tures of RA are ameliorated in approximately 75% of 
pregnant patients who have high serum levels of E2 and 
progesterone [53]. Notably, relapses are frequent in the 
postpartum period when the levels of these hormones 
fall [54]. Clinical trials examining the effects of oral con-
traceptives or hormone replacement therapy on the se-
verity or progression of existing RA in postmenopausal 
women have yielded contrasting results, some studies 
showing evidence of a beneficial effect of estrogens and 
other studies finding no effect [40]. Finally, active RA is 
characterized by an activity peak early in the morning 
which correlates with prolactin plasma levels [55].
Regarding male sex hormones, the available data sug-
gest that the onset and severity of RA are inversely as-
sociated with androgen levels, providing a possible ex-
planation for the increased rate of RA incidence in men 
after 55 years and for the less severe disease course in 
men as compared to females [56, 57]. Men also have 
a better response to RA therapy than women [58]. In-
terestingly, there is evidence that some RA patients of 
both sexes have reduced amounts of serum androgens 
already several years before disease onset. In particu-
lar, female RA patients have lower than normal levels 
of dehydroepiandrosterone and/or dehydroepiandros-
terone sulfate. Androgen replacement therapy has posi-
tive effects in male RA patients, particularly as adjuvant 
treatment [59], and a slight disease-modifying effect, 
not statistically significant, in postmenopausal women 
with RA [60]. There is incomplete information on ge-
netic influences on sex disparities in RA. Recently, poly-
morphisms in the CYB5A gene, which is relevant for 
androgen synthesis, have been found to be associated 
with risk of RA in women, but not men, thus contrib-
uting to the sex bias observed in RA [61]. In contrast 
to SLE, RA has been described very rarely in patients 
with Klinefelter syndrome, suggesting that the extra 
X chromosome does not confer an added risk for RA. 
One study found an association between RA and single 
nucleotide polymorphisms (SNP) of the X-encoded 
genes TIMP1 (which inhibits matrix metalloproteinases 
and prevents cartilage degradation) and IL-9 receptor 
(which is involved in IL-9 signaling and in early T cell 
development) [62]. To date, no data are available on 
epigenetic modification of the inactivated X chromo-
some in relation to RA susceptibility. Sex-specific fac-
tors affecting RA are summarized in Table 2.
MULTIPLE SCLEROSIS
MS affects 1 in 1000 people in Western countries and 
is the most common chronic inflammatory disease of 
the central nervous system causing neurological disabil-
ity. MS is usually diagnosed in young adults and charac-
terized by bouts and remissions followed by a secondary 
progressive course. Less frequently, MS has a progres-
sive course right from the onset. MS affects women 
two to three times as often as men. While females are 
at higher risk for MS, males are more likely to display 
primary progressive disease and accumulate disability 
faster than female patients in relapse-onset MS [63]. 
The sex ratio in MS appears to be rising; this trend is 
Table 1
Sex specific factors affecting systemic lupus erythematosus
Hormones Accelerated metabolic conversion of androgen precursors to E2 (aromatase activation) [38]E2 effects on immune function [3, 34]
Genetic factors X-linked genes (FOXP3, TNF, TLR7) [5]
Epigenetic factors
X-linked miRNAs [22]
Estrogen up-regulated miRNA (miR148a) [22]
Estrogen down-regulated miRNA (miR146a, miR125a) [46]
Clinical phenotype Incidence of Raynaud’s phenomenon, alopecia, malar rash and arthralgia/arthritis higher in females than in males [47]
Sex and autoimmunity
M
o
n
o
g
r
a
p
h
ic
 s
e
c
t
io
n
209
noted primarily in relapsing-remitting MS and is associ-
ated with a latitudinal gradient [64]. 
As for other autoimmune diseases, the cause of MS is 
not well understood but a complex interaction between 
genetic and environmental factors is clearly involved. 
The HLA-DR2 allele within the MHC region is the 
major genetic risk factor for MS [65]. In recent MS ge-
nome wide association studies, 110 variants have been 
identified outside the HLA region, which are typically 
common, mostly related to immune system function 
and have very modest effects on disease risk [66]. To 
date, none of the studies of HLA and non HLA genes 
have convincingly shown that genetic differences be-
tween women and men affect MS susceptibility. Also, 
no MS susceptibility loci are confirmed to be located on 
the X chromosome. 
The role of hormonal changes in the modulation of 
MS risk and course in female patients has been exten-
sively investigated. Puberty and pregnancy have re-
ceived much attention in MS research, while the impact 
of breastfeeding, oral contraceptives use, menopause 
and HRT on MS risk and course is less understood. Af-
ter puberty there is a dramatic, female-specific increase 
in MS risk; earlier puberty and obesity during child-
hood are significant risk factors for MS [67]. Female 
MS patients experience clinical improvements during 
pregnancy, particularly in the last trimester, with a re-
bound in relapses occurring in the first trimester post-
partum [68]. Specific changes in the expression of a 
limited number of immune-related genes during preg-
nancy were found associated with a decrease in MS dis-
ease activity assessed by occurrence of relapses during 
pregnancy [69]. Testosterone, progesterone and estriol, 
the major estrogen during pregnancy, have been found 
to induce anti-inflammatory as well as neuroprotective 
effects in preclinical models of MS, suggesting the po-
tential use of these hormones for the treatment of MS 
[70]. Lower testosterone levels have been associated 
with higher disability in men with MS [71]. The results 
of two phase 2 trials of transdermal testosterone in male 
MS patients [72] and oral estriol in female MS patients 
[73] are encouraging but warrant further investigation 
in phase 3 trials.
Findings of an increasing sex ratio in MS implicate 
heightened female responsiveness to changing cultural 
and environmental cues. Vitamin D deficiency, Epstein-
Barr virus infection and smoking history are known to 
influence MS risk [74]. Recent studies indicate that cig-
arette smoking is also a risk factor for disease progres-
sion [75]. However, it is still poorly understood how en-
vironmental factors interact with hormones, metabolic 
factors, including diet and/or altered gut microbiota, 
and a susceptible genetic background to shape MS. 
Sex-related differences in neuroimaging features [76], 
cerebrospinal and peripheral blood biomarkers [77, 
78] and effectiveness of first- and second-line therapies 
for MS need to be thoroughly explored to yield new 
insights into MS pathological mechanisms and help in 
treatment decisions in the growing armamentarium of 
drugs that can ameliorate MS. Sex-specific factors af-
fecting MS are summarized in Table 3.
CONCLUSIONS
Differences in prevalence and severity of autoim-
mune diseases between males and females result from 
complex and still poorly understood interactions be-
tween genetic, hormonal and environmental factors. 
The increasing use of multi-omics and bioinformatic 
approaches in large and clinically well characterized 
patient cohorts will help identify critical pathways and 
Table 2
Sex specific factors affecting rheumatoid arthritis
Hormones
Estrogen effects on immune function (both pro-inflammatory and anti-inflammatory effects, induction of Tregs) 
[50]
Progesterone effects on immune function (anti-inflammatory effects, induction of Tregs) [50]
Androgen effects on immune function (anti-inflammatory effects) [57]
High aromatase activity in synovial fluid (® prevalence of synovial estrogens relative to androgens) [52]
Genetic factors Single nucleotide polymorphisms of the CYB5A gene in RA females [61]Single nucleotide polymorphisms of the X-encoded genes TIMP1 and IL-9R [62]
Clinical phenotype Less severe course of illness and better response to therapy in males as compared to females [56, 58]Amelioration of RA in pregnant females [53]
Table 3
Sex specific factors affecting multiple sclerosis
Hormones
Female specific increase in MS risk after puberty [67]
Neuroprotective and anti-inflammatory effects of testosterone, progesterone and estriol in MS-like disease 
models [70]
Dramatic decrease in MS relapse frequency during the second half of pregnancy, followed by a rebound in 
relapses in the first trimester postpartum [68]
Genetic factors Still unknown
Clinical phenotype Faster accumulation of disability in male than female patients in relapse-onset MS [63]
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networks that can be useful for the discovery of new 
biomarkers and targeted for sex-specific therapeutic in-
tervention and/or prevention of autoimmune diseases.
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